Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, and advisor to MedTech suppliers, shares a breakthrough in testing for prostate cancer.
The NHS is trialling an AI-powered “one-day diagnostics” service for prostate cancer that could shorten diagnosis timelines by up to a month for some men. The pilot uses an artificial intelligence tool to interpret MRI scans within minutes, flagging suspicious lesions and enabling a rapid pathway that can deliver investigation and next steps on the same day.
How the pathway will work
The trial, funded by NHS England, begins with a pilot at Leeds Teaching Hospitals NHS Trust early next year and may run across as many as 15 hospitals. Men with suspected prostate cancer will receive MRI scans that are rapidly analysed by the AI system. Scans identified as high risk by the software will be prioritised for immediate radiologist review and, where appropriate, patients will be booked for a biopsy on the same day. For men whose scans are assessed as low risk, clinicians will have the information needed potentially to give an all-clear during the visit or confirm a diagnosis a few days later after review.
Expected benefits and scale
If successful, the rapid diagnosis pathway could reduce weeks of waiting, easing anxiety for patients and accelerating the start of treatment when needed. The Leeds pilot aims to increase the number of patients diagnosed or ruled out within 28 days. In other trial sites the AI tool will assist radiologists across approximately 10,000 scans to support decisions about active surveillance, biopsy and treatment planning. Research cited by the programme suggests the tool can detect around 95% of cancers. Wider rollout across the NHS could lead to thousands being diagnosed and treated sooner.
Bringing care closer to home and improving capacity
Faster AI-assisted MRI reporting could shift some diagnostic work into Community Diagnostic Centres, moving care closer to patients’ homes and reducing pressure on hospital imaging departments. The trial is positioned as a method to boost diagnostic capacity without proportionally increasing radiologist workloads. By triaging suspicious scans automatically, the pathway aims to make better use of specialist time and reduce bottlenecks that currently lengthen waits in some areas.
Clinical perspective and patient story
NHS clinical leaders describe the pilot as a potential game changer. The national clinical director for cancer highlighted speed as critical to better outcomes and reduced distress for patients and families. At Leeds, the consultant radiologist leading the trial emphasised the goal of fast-tracking patients who need further investigation so MRI, biopsy and initial discussion can happen in one visit at the Leeds Cancer Centre.
A patient case quoted by the programme illustrates the emotional toll of diagnostic delay. A man who ignored symptoms eventually secured rapid scans and a biopsy that led to a stage 3B prostate cancer diagnosis. He received hormone therapy and radiotherapy and now undergoes regular PSA monitoring. He reflected that a reliable single-day diagnostic service would have spared weeks of worry and potentially eased strains on relationships.
Wider policy and funding context
The project forms part of a broader NHS and government push to diagnose cancer earlier and more efficiently. It is one of seven innovative pilots backed by a 14 million GBP investment aimed at improving early detection through the NHS Cancer Programme Innovation Open Call. Health ministers and patient charities have welcomed the trial as a step toward fairer, faster access to accurate diagnosis that could reduce unnecessary hospital trips and free clinician capacity.
The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
